Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Sensei Biotherapeutics is a clinical-stage biotech focused on developing next-generation cancer immunotherapies. Using its TMAb platform, it creates highly selective biologics that modulate the tumor microenvironment by targeting immune checkpoints like VISTA. Its products aim to enhance anti-tumor immune responses, often in combination with existing therapies, serving patients with various solid tumors through innovative, tumor-specific mechanisms.
This description was generated via AI from an annual report. Updated about 1 year ago.